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RESEARCH ON METHODS – Study Design
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COMPREHENSIVE REVIEW OF EMPLOYER-SPONSORED WELLNESS STRATEGIES
AND THEIR ECONOMIC AND HEALTH-RELATED OUTCOMES: EVIDENCE
QUALITY AND OPPORTUNITIES FOR FUTURE RESEARCH
Kaspin LC1, Gorman KM1, Miller RM2
1Cerner LifeSciences Consulting, Beverly Hills, CA, USA, 2Cerner Health Connect, Beverly Hills,
CA, USA
OBJECTIVES: A rising number of companies are sponsoring wellness programs to
improve employee health and reduce health care costs. This review sought to
determine the characteristics and outcomes of employer-sponsored wellness pro-
grams and determine possible reasons for their success. METHODS: PubMed, ABI
Inform, and Business Source Premier databases and Corporate Wellness Magazine
were searched. English-language articles published from 2005-2011 reporting char-
acteristics of employer-sponsored wellness programs and their impact on health-
related and economic outcomes amongUS employeeswere accepted. Animal stud-
ies, non-US-based studies, letters, editorials, and economic models were not
accepted. Data were abstracted, synthesized, and interpreted. RESULTS: Twenty
references were accepted. Wellness interventions were classified into health as-
sessments, lifestyle management, and behavioral health. While improved eco-
nomic outcomes were reported for companies with wellness programs (ie, total
health care costs, return on investment, absenteeism, productivity, workers’ com-
pensation, utilization) as well as decreased health risks, cause-and-effect relation-
ships could not be determined. Fourteen accepted articles were published in mag-
azines and four in newspapers. Only three were published in peer-reviewed
journals and those articles were the only ones to report a study design: 2 were
described as quasi-experimental and the third a survey. Most articles described
one company’s wellness programs and outcomes, with some reporting changes
over time. Some of the reported wellness programs were not described in full
detail. Multiple types of outcomes were described across accepted articles, which
precluded comparisons of an individual outcome across studies. Some articles
described multiple interventions, making it difficult to assess benefits from indi-
vidual interventions. CONCLUSIONS: While employer-sponsored wellness pro-
grams are being reported along with improved outcomes, there are limited defin-
itive data on a cause-and-effect relationship. Further research, of a high
methodological caliber, is needed to support informed decisions. Specifically, ran-
domized trials and economic analyses would empower employers with the infor-
mation needed to implement successful wellness programs.
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SYSTEMATIC REVIEW OF GUIDELINE RECOMMENDATIONS ON COMPARATOR
SELECTION IN HEALTH ECONOMIC EVALUATIONS
Wagner M, Melnyk P, Rindress D
BioMedCom Consultants Inc., Dorval, QC, Canada
OBJECTIVES: Choice of comparator(s) is a critical design parameter for any health
economic evaluation (HE). HE guidelines may differ in their recommendations on
this issue. We reviewed all accessible HE guidelines to identify shared themes and
differences within their recommendations on comparator selection. METHODS:
We systematically searched PubMed/Medline, the Centre for Reviews and Dissem-
ination, the EQUATOR network, and websites of health technology assessment
agencies andhealthcare coverage decisionmaking bodies for publicly accessible HE
guidelines. Guidelineswere classified as jurisdictional mandatory or non-mandatory or
as general. Following review and parsing, data was extracted into a template and
recommendations were coded under common, non-mutually exclusive themes.
Both qualitative and quantitative analyses were performed. RESULTS: Seventy-
four HE guidelineswere identified and reviewed, of which 74%mentioned the issue
of comparators: 96% of jurisdictional mandatory, 91% of jurisdictional non-man-
datory and 58% of general guidelines. The most frequent recommendations with
respect to comparator selection were to use themost common treatment (70.9% of
all guidelines), to include “no intervention” when appropriate (41.8%), and to use
best practice (e.g., guideline-or specialist recommended treatment) as comparator
(29.1%). Other recommendations were to compare with the treatment most likely
to be replaced (18.2%), to use all alternative treatments (16.4%), and the least costly
treatment (14.5%). Almost half (45.5%) of guidelines specified justification of choice
of comparator and 21.8% detailed description of all comparators. Mandatory juris-
dictional guidelines weremore likely than general guidelines to specify most com-
mon treatment (86.4% vs. 47.8%, P0.01 Fisher’s exact test), whereas general guide-
lines were more likely to recommend all alternative forms of therapy (30.4% vs.
4.5%, P0.05). CONCLUSIONS: Although there are common themes among guide-
lines on comparator selection, differences exist of whichmodel developers need to
be aware.
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SOURCE DATA VERIFICATION IN OBSERVATIONAL STUDIES: REVIEW OF
CURRENT PRACTICE
Velthuis EJ1, Richards MS2, Malka ES2
1PPD, Bennekom, The Netherlands, 2PPD, Morrisville, NC, USA
OBJECTIVES: Post-approval product research in the form of observational study is
increasingly prominent. Observational studies inform real-world safety and effec-
tiveness. Lack of specific regulatory requirements or guidances for source data
verification (SDV) in these studies, however, leaves sponsors and partner CROs to
determine the level of SDV necessary to ensure quality. A literature review was
performed to determine the level of SDV in practice in published observational
studies. METHODS: Google Scholar and Pubmed searches were used to retrieve
relevant publications. The term ‘source data verification’ was used in combination
with the terms ‘observational study’ and ‘non-interventional study’. Articles read-
ily available in full text were included for analysis. The methods sections were
screened to determine the level of SDV applied. If multiple publications referred to
a single study or registry, only one representative publication was selected for
inclusion. RESULTS: Of the observational studies included, 37 studies mentioned
SDV in their methods section. Of these, 16 (43%) did not further specify the level of
SDV. In the remaining 21 studies, SDV ranged from0 to 100%,with amedian of 10%.
Subject numbers in these 21 studies ranged between 135 and 19,870 (median: 864.)
These studies were mainly prospective (14/21) and were conducted in the EU (16/
21), China (1/21), Australia (1/21), the Philippines (1/21) and worldwide (2/21). The
majority (16/21) of the studies were reported to be funded by the pharmaceutical
industry. Generally, studies larger than 1000 subjects sought to verify data sources
for only 10% of their population. CONCLUSIONS: The level of SDV is not routinely
specified in themethods section of observational study publications. In those pub-
lications that did elaborate on study quality, the level of SDV ranges between 0%
and 100%,with large (n1000 subjects) observational studies restricting the level of
SDV to a maximum of 10%.
RESEARCH ON METHODS – Conceptual Papers
PRM54
A CONCEPTUAL ANALYSIS OF WHEN MEDICAL EXPENDITURE PANEL SURVEY
(MEPS) MEETS COST OF ILLNESS (COI) – ARE THEY A MATCH?
Coughlan D, Frick KD
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
OBJECTIVES:MEPS has been used as a data source for many direct medical expen-
ditures (DME)/COI type studies. The objective of this conceptual analysis is to re-
view the literature & evaluate the 4 main COI type studies with reference to pa-
tients with head and neck cancer (HNC) using the MEPS data source. METHODS:
The 4main COI methods are 1) Sum_All Medical; 2) Sum_Diagnosis Specific; and 3)
Matched Control (iv) Regression. Without a comparison group, analysts use a total
cost approach. With a comparison group, an incremental cost approach is most
often reported. ISPOR does not have standard guidelines in reporting COI studies;
analysts often vary in their perspective, but should alwaysmake reference tomed-
ical costs, morbidity & mortality costs, transportation/nonmedical costs and pro-
ductivity losses in their analysis. RESULTS: A review of recent COI type papers
(n10) that have usedMEPS shows that analysts report findings based on usually 1
COI method. Only 2 studies (COPD & Diabetes) reported both total and incremental
cost approaches in their analysis. Four studies merged condition, event and con-
solidated year files, which allows diagnosis specific estimates to be produced. As a
conceptual analysis, HNC is used to illustrate that MEPS facilitates analysts to use
the 4 main COI methods especially if DME is the outcome of interest.
CONCLUSIONS:MEPS is a valuable and utilized national resource. It is possible that
“good practice guidelines” can be developed (& perhaps endorsed by AHRQ) for
those using MEPS to report a DME/COI type study. By using & reporting all 4 meth-
ods, an analyst is giving policy-makers a range for their cost estimates. Guidelines
would ensure a level of transparency in reporting such cost estimates across con-
ditions.
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MODELING THE PROGRESSION OF CHRONIC DISEASES IN A DYNAMIC MARKET:
IMPLICATIONS FOR BUDGET IMPACT ANALYSIS
Eldar-Lissai A1, Banerjee R1, Mcbride S2, Leaf-herrmann W1
1Analysis Group, Inc., Boston, MA, USA, 2Analysis Group, Inc., Menlo Park, CA, USA
The ISPOR task force guidelines on good research practices for Budget Impact Anal-
yses (BIA) identify two simultaneous processes affecting themarketplace: changes
in the mix and evolution of available interventions over time (i.e., market share)
and changes in the target population resulting from various disease characteristics
(e.g., incidence, progression and death). Inmany chronic diseases, disease severity
changes over time and thus medical costs vary across disease cohorts. Hence, in a
budget impact model two constraints must be met: 1) the number of patients
progressing from one year to the next corresponds to known disease statistics (i.e.,
patients who enter the model cannot be ‘lost to follow-up’), 2) the total number of
treated patients conforms with known population size and projected market
shares. The current guidelines lack detail on how to satisfy these two constraints
simultaneously in dynamicmarkets with non-trivial rates of patient attrition from
treatment groups. OBJECTIVES: To identify a method that allows researchers to
more accurately model the budget impact of new interventions for chronic dis-
eases in dynamic markets. METHODS: We propose a simple adjustment factor
which is a function of disease and treatment’s attrition rate in two consecutive
years to correct the allocation of patients across disease cohorts such that the two
constraints identified above are always met simultaneously. We compare two set-
tings (static vs. dynamic markets) and analyze the implications over a time period
of five years. RESULTS: We find that applying the adjustment factor in dynamic
markets reduces the bias in budget impact measures by 15% or more and contend
that not correcting for this inmore complexmarkets would lead to higher bias. Our
proposed solution is a simple way of accounting for differential rates of attrition
across treatments in a chronic disease setting in budget impact analyses.
PRM57
COST-EFFECTIVENESS ANALYSIS IN PERSONALIZED MEDICINE: GENERAL
HYPOTHESES AND CORRESPONDING DECISION TREE STRUCTURES FOR
SCREENING, DIAGNOSTIC, PREDICTIVE, PROGNOSTIC, SURVEILLANCE, AND
MONITORING TESTS
Mladsi DM, Herring WL, Earnshaw SR
RTI Health Solutions, Research Triangle Park, NC, USA
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OBJECTIVES: Personalized medicine is characterized by an increasing number of
tests andpayer scrutiny over their value. Depending on the use of a test, health care
costs and outcomes may change in predictable ways. METHODS: We describe six
uses of tests, matching each with value hypotheses and a generic decision tree
framework thatmay be used to study test cost-effectiveness.Wemake distinctions
between screening (to identify those in a population likely to have or develop a
disease), diagnostic (to diagnose), predictive (to predict response to or toxicity from
a particular treatment, often referred to as a companion diagnostic), prognostic (to
identify patients at risk for a specific outcome, regardless of the choice of treat-
ment), surveillance (for patients with no sign of disease at completion of treatment
to identify those at risk of recurrence), andmonitoring (to detect response to treat-
ment or disease progression) tests. We specify how each test is expected to affect
health care costs and/or outcomes, followed by the nature and direction of the
effects.We also show the importance of properlymodeling the distinction between
these tests. For example, by identifying earlier or more accurately patients at
higher risk, a new screening test may lead to diagnosis at lower levels of disease
severity, resulting (from treatment) in improved life expectancy (LE) and/or quali-
ty-adjusted LE. Also, by identifying patients at lower risk, a new screening testmay
reduce costs associated with unnecessary future testing. Comparatively, we find
that salient elements of a general model structure for a new screening test include
screening compliance and distribution by severity at diagnosis, which are less
pertinent to other test uses. CONCLUSIONS: Testsmay be expected to affect health
care costs and outcomes in predictableways depending on the type of test; we offer
model structures that reflect these distinctions.
PRM58
TURNING THE IMPLAUSIBLE TO THE PLAUSIBLE: TOWARDS A BETTER
CONTROL OF OVER THE COUNTER DISPENSING OF ANTIBIOTICS IN EGYPT
Khalil RB
ISPOR-Egypt Chapter, Cairo, Manial, Egypt
As a developing country, Egypt has long suffered negative outcomes from irrational
drug dispensing practices. This affected health economics adversely and increased
the burden of antibiotic resistance. With limited research data on this specific area
in Egypt, it becomes imperative to guide the researchers to potential adverse ef-
fects of over-the-counter dispensing on antibiotic resistance prevalence. This re-
search aims to define the flaws in antibiotic dispensing in Egypt and its impact on
the access to antibiotics. Spending on pharmaceuticals in Egypt constitutes 34% of
the total health care spending. TheMinistry of Health and Population has enforced
several laws prohibiting over-the-counter dispensing of drugs. However, there is
limited evidence on the effectiveness of those regulations on inappropriate dis-
pensing. Literature review revealed that only one report that dates back to 1998
addressed this area of inquiry. Analysis of 1174 dispensed products in 25 different
districted pharmacies in Alexandria showed that 60% of medications dispensed
were without a prescription or a pharmacist recommendation. Among those prod-
ucts, there were 98 different antibiotic products of which 42% were dispensed
without a prescription. Over all, Egypt suffers a high percentage of over-the-coun-
ter dispensing of drugswith little studies paying attention to this aspect in terms of
antibiotic resistance patterns. Despite enforced laws prohibiting over-the-counter
dispensing of drugs, further interventions are required. More strict laws must ap-
ply to pharmacists who do not complywith the official regulations of drug dispens-
ing. Further studies should inquire into non-optimal dispensing practices. Educa-
tional campaigns for patients to increase their level of awareness are crucial to
decrease wasteful drug spending and ensure approximate containment of newly
emerging antibiotic resistance in the near future.
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TRADE-OFF ANALYSIS: AN EXTENSION OF THRESHOLD PRICING ANALYSIS
Mladsi DM, Graham JB, Ronquest N
RTI Health Solutions, Research Triangle Park, NC, USA
BACKGROUND: Investment decisions aremade on the basis of whether a new drug
is expected to meet certain criteria specified in a target product profile (TPP). Sim-
ilarly, such decisions assume a target price, which is used in calculations of return-
on-investment. Assuming a payer-cost-effectiveness threshold, threshold pricing
models are used to estimate themaximumvalue-based price assuming a new drug
achieves its TPP, and to estimate minimum value-based efficacy, safety, and toler-
ability required to support a target price. To assess the effects of uncertainty, one-
way and probabilistic sensitivity analyses may be tailored to apply to threshold
pricing models; however, to assess the risk to attaining a target price if a new drug
were to fail to achieve a particular criterion, it is essential to understand the rela-
tionships among the criteria listed in the TPP.METHODS:Wedescribe an extension
of threshold pricing analysis to include trade-off assessment. For example, a new
drug may be expected to reduce the risk of hospitalization, reduce hospital length
of stay, and reduce mortality, each by a certain amount, the combined achieve-
ment of which supports a particular value-based priced. Using trade-off analysis, it
is possible to estimate the improvement required in one attribute to offset the
failure of the new drug to achieve the expected effect in another attribute. In our
example, trade-off analysismay suggest that if the newdrugwere to fail to produce
an expected 5% mortality reduction, the new drug will need to quadruple the
reduction in hospital length of stay to achieve the same value based price. We
present tabular and graphical depictions of how multiple target attribute levels
may offset each other in a new drug’s ability to achieve a value-based price.
CONCLUSIONS: Trade-off analyses when applied to a threshold-pricingmodel can
make important contributions to value-based product development.
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OPERATIONALISING MULTIPLE CRITERIA DECISION ANALYSIS FOR HEALTH
TECHNOLOGY ASSESSMENT
Thokala P
University of Sheffield, Sheffield, UK
OBJECTIVES: To discuss the different methods of multi criteria decision analysis
(MCDA) that could be used in health technology assessment (HTA) and their rela-
tive merits. METHODS: The current practice of health technology appraisals is
based on the incremental cost-effectiveness ratio (ICER) i.e. the incremental cost
per quality adjusted life year (QALY) gained by recipients of treatment. Even though
other factors (e.g. severity, life saving, etc) are considered alongwith ICERs, there is
concern that its approach may fail to capture other important sources of value.
MCDA is aimed at supporting decision makers faced with evaluating alternatives
taking into account multiple, and often conflictive, criteria in an explicit manner.
This paper addresses a number of important questions to identify the most appro-
priate MCDAmethod that might be used to support decisionmaking. For example,
what criteria should be incorporated? Whose weights should be used and how to
elicit them? How to incorporate uncertainty into the MCDA process? How do we
consider the value of displaced technologies? What should the ‘basic’ cost-effec-
tiveness threshold be? How do we estimate it? This paper will discuss these ques-
tions, outline and assess methodological issues that would be raised by the use of
MCDA in health technology assessment (HTA). RESULTS: A potential MCDA ap-
proach for HTA is to calculate “weighted” QALYs from the QALY weights which
reflect the broader value of the product’s benefits and compare against the updated
“basic threshold” value. CONCLUSIONS: There are general practical issues that
might arise from using this MCDA approach in the HTA process and further re-
search needs to be performed to address the issues identified in order to ensure the
success of this MCDA technique in the appraisal process.
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IF YOU HAVE 2 WATCHES THEN WHAT TIME IS IT ? SELECTING A DEFINITIVE
SOCIAL VALUE SET FOR MEASURING HEALTH GAINS
Kind P1, Chuang LH2
1University of York, York, UK, 2York Trials Unit, York, UK
Regulatory authorities inmany countries require that societal preferences are used
when health (dis)benefits are reported in terms of quality-adjusted life-years
(QALYs). In the United Kingdom the NICE reference case, as set out in its published
technical guidance, cites EQ-5D as the requisite health-related quality of life
(HrQoL) system and Time Trade-Off (TTO) as the preferred method for eliciting
societal values. This stipulation is simple to assert, but virtually impossible to
justify and/or operationalise in practice. Nevertheless this has been the UK default
position for many years and has established a de facto national “norm”. These
issues, however, are global in nature and common to economic evaluation of
healthcare in all countries. TheUK “preference” for TTO is nomore than that, for no
scientific case has been made for rejecting Standard Gamble (SG), commonly ac-
knowledged to yield systematically different estimates of utility. Both methods
cannot be correct - one (at least) must be in error. It is patently absurd to consider
them as commensurable equivalents in QALY calculations. In principle, a similar
difficulty arises as new value sets are published, as will be the case in respect of the
5-level version of EQ-5D. Cost-utility analysis reported in the literature reveals a
10-fold difference in incremental benefits (change frombaseline)when EQ-5D/HUI/
SF-6D are used to compute QALYs, sufficient to reverse the location of an ICERwith
respect to any threshold. The central issue is that of updating the choice of a
definitive value set for reference case analysis. This paper argues for a decision-
centric approach inwhich a newmetricmay only be adopted if its use inmeasuring
incremental effectiveness yields results that are consistentwith those based on the
existing reference standard. The argument is exemplified through the analysis of
EQ-5D in published studies.
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VISUAL ASSESSMENT OF FIT OF EQUATIONS TO PREDICT TIME-TO-EVENT
OUTCOMES
Ishak K
United BioSource Corporation, Dorval, QC, Canada
Graphical tests are very useful for assessing the fit of statistical models. In linear
regressionmodels, for instance, a plot of predicted means against observed values
can reveal systematic over- or under-prediction. Similar graphical tests are not
necessarily straightforward for other types of regression models like those based
on parametric survival distributions (e.g., to predict life-expectancy, time to pro-
gression of disease), particularly when multiple predictors are included in the
model. The first complicating issue is censoring, which makes a scatter plot of
individual observed and predicted values difficult to interpret. A better approach is
to plot the empirical distributions (i.e., Kaplan-Meier curves) derived from the ob-
served and predicted values, which inherently accounts for censoring in observed
times. The second andmore intricate issue is the definition of the predicted values.
In linear regression models, predictions represent the mean of the underlying
normal distribution that produced the observation. Since the normal distribution is
symmetric, it is reasonable to expect half of the observations to fall below their
means, and the rest to fall above. Parametric survival distributions are highly
skewed, however, so that the mean would generally be expected to exceed most
observed values. Similar problems arise if one uses the median (or any one partic-
ular percentile) as a reference, or plots the overall predicted curve at the mean
predicted value of the regression parameter (i.e., the scale of the distribution). An
accurate depiction of the overall predicted curve can be obtained instead by gen-
eratingmultiple randomevent times from each individual’s predicted distribution,
and using these to derive the overall predicted curve. The approach will be illus-
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